Copley will not reintroduce albuterol .5% solution following $150 mil. litigation settlement.
COPLEY ALBUTEROL .5% SOLUTION WILL NOT BE REINTRODUCED, the company said following the announcement Aug. 22 of a $150 mil. settlement of litigation arising from its January 1994 Class I recall of the generic asthma product. The company previously had been projecting a reintroduction of the product by early 1996: in May, Copley Chairman Kenneth Larson told a Dillon, Read generic drugs conference that Copley planned to reintroduce the albuterol solution to the market in the next 12 months ("The Pink Sheet" May 22, T&G-17).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth